Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression

Jun Itakura, Toshiyuki Ishiwata, Helmut Friess, Hideki Fujii, Yoshiro Matsumoto, Markus W. Büchler, Murray Korc

Research output: Contribution to journalArticle

224 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) is an angiogenic polypeptide that has been implicated in cancer growth. In the present study, we characterized VEGF expression in cultured human pancreatic cancer cell lines and determined whether the presence VEGF in human pancreatic cancers is associated with enhanced neovascularization or altered clinicopathological characteristics. VEGF mRNA transcripts were present in all six tested cell lines (ASPC-1, CAPAN-1, MIA-PaCa-2, PANC-1, COLO-357, and T3M4). Immunoblotting with a highly specific anti-VEGF antibody revealed the presence of VEGF protein in all of the cell lines. Northern blot analysis of total RNA revealed a 5.2-fold increase in VEGF mRNA transcript in the cancer samples in comparison with the normal pancreas. Immunohistochemical and in situ hybridization analysis confirmed the expression of VEGF in the cancer cells within the tumor mass. Immunohistochemical analysis of 75 pancreatic cancer tissues revealed the presence of strong VEGF immunoreactivity in the cancer cells in 64% of the cancer tissues. The presence of VEGF in these cells was associated with increased blood vessel number, larger tumor size, and enhanced local spread but not with decreased patient survival. These findings indicate that VEGF is commonly overexpressed in human pancreatic cancers and that this factor may contribute to the angiogenic process and tumor growth in this disorder.

Original languageEnglish (US)
Pages (from-to)1309-1316
Number of pages8
JournalClinical Cancer Research
Volume3
Issue number8
StatePublished - Aug 1997
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Vascular Endothelial Growth Factor A
Disease Progression
Neoplasms
Cell Line
human VEGFA protein
Growth Disorders
Messenger RNA
Immunoblotting
Northern Blotting
In Situ Hybridization
Blood Vessels
Pancreas
RNA
Peptides
Survival
Antibodies
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Itakura, J., Ishiwata, T., Friess, H., Fujii, H., Matsumoto, Y., Büchler, M. W., & Korc, M. (1997). Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clinical Cancer Research, 3(8), 1309-1316.

Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. / Itakura, Jun; Ishiwata, Toshiyuki; Friess, Helmut; Fujii, Hideki; Matsumoto, Yoshiro; Büchler, Markus W.; Korc, Murray.

In: Clinical Cancer Research, Vol. 3, No. 8, 08.1997, p. 1309-1316.

Research output: Contribution to journalArticle

Itakura, J, Ishiwata, T, Friess, H, Fujii, H, Matsumoto, Y, Büchler, MW & Korc, M 1997, 'Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression', Clinical Cancer Research, vol. 3, no. 8, pp. 1309-1316.
Itakura J, Ishiwata T, Friess H, Fujii H, Matsumoto Y, Büchler MW et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clinical Cancer Research. 1997 Aug;3(8):1309-1316.
Itakura, Jun ; Ishiwata, Toshiyuki ; Friess, Helmut ; Fujii, Hideki ; Matsumoto, Yoshiro ; Büchler, Markus W. ; Korc, Murray. / Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 8. pp. 1309-1316.
@article{bb388ee825d14855bf2be2d22a191d38,
title = "Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression",
abstract = "Vascular endothelial growth factor (VEGF) is an angiogenic polypeptide that has been implicated in cancer growth. In the present study, we characterized VEGF expression in cultured human pancreatic cancer cell lines and determined whether the presence VEGF in human pancreatic cancers is associated with enhanced neovascularization or altered clinicopathological characteristics. VEGF mRNA transcripts were present in all six tested cell lines (ASPC-1, CAPAN-1, MIA-PaCa-2, PANC-1, COLO-357, and T3M4). Immunoblotting with a highly specific anti-VEGF antibody revealed the presence of VEGF protein in all of the cell lines. Northern blot analysis of total RNA revealed a 5.2-fold increase in VEGF mRNA transcript in the cancer samples in comparison with the normal pancreas. Immunohistochemical and in situ hybridization analysis confirmed the expression of VEGF in the cancer cells within the tumor mass. Immunohistochemical analysis of 75 pancreatic cancer tissues revealed the presence of strong VEGF immunoreactivity in the cancer cells in 64{\%} of the cancer tissues. The presence of VEGF in these cells was associated with increased blood vessel number, larger tumor size, and enhanced local spread but not with decreased patient survival. These findings indicate that VEGF is commonly overexpressed in human pancreatic cancers and that this factor may contribute to the angiogenic process and tumor growth in this disorder.",
author = "Jun Itakura and Toshiyuki Ishiwata and Helmut Friess and Hideki Fujii and Yoshiro Matsumoto and B{\"u}chler, {Markus W.} and Murray Korc",
year = "1997",
month = "8",
language = "English (US)",
volume = "3",
pages = "1309--1316",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression

AU - Itakura, Jun

AU - Ishiwata, Toshiyuki

AU - Friess, Helmut

AU - Fujii, Hideki

AU - Matsumoto, Yoshiro

AU - Büchler, Markus W.

AU - Korc, Murray

PY - 1997/8

Y1 - 1997/8

N2 - Vascular endothelial growth factor (VEGF) is an angiogenic polypeptide that has been implicated in cancer growth. In the present study, we characterized VEGF expression in cultured human pancreatic cancer cell lines and determined whether the presence VEGF in human pancreatic cancers is associated with enhanced neovascularization or altered clinicopathological characteristics. VEGF mRNA transcripts were present in all six tested cell lines (ASPC-1, CAPAN-1, MIA-PaCa-2, PANC-1, COLO-357, and T3M4). Immunoblotting with a highly specific anti-VEGF antibody revealed the presence of VEGF protein in all of the cell lines. Northern blot analysis of total RNA revealed a 5.2-fold increase in VEGF mRNA transcript in the cancer samples in comparison with the normal pancreas. Immunohistochemical and in situ hybridization analysis confirmed the expression of VEGF in the cancer cells within the tumor mass. Immunohistochemical analysis of 75 pancreatic cancer tissues revealed the presence of strong VEGF immunoreactivity in the cancer cells in 64% of the cancer tissues. The presence of VEGF in these cells was associated with increased blood vessel number, larger tumor size, and enhanced local spread but not with decreased patient survival. These findings indicate that VEGF is commonly overexpressed in human pancreatic cancers and that this factor may contribute to the angiogenic process and tumor growth in this disorder.

AB - Vascular endothelial growth factor (VEGF) is an angiogenic polypeptide that has been implicated in cancer growth. In the present study, we characterized VEGF expression in cultured human pancreatic cancer cell lines and determined whether the presence VEGF in human pancreatic cancers is associated with enhanced neovascularization or altered clinicopathological characteristics. VEGF mRNA transcripts were present in all six tested cell lines (ASPC-1, CAPAN-1, MIA-PaCa-2, PANC-1, COLO-357, and T3M4). Immunoblotting with a highly specific anti-VEGF antibody revealed the presence of VEGF protein in all of the cell lines. Northern blot analysis of total RNA revealed a 5.2-fold increase in VEGF mRNA transcript in the cancer samples in comparison with the normal pancreas. Immunohistochemical and in situ hybridization analysis confirmed the expression of VEGF in the cancer cells within the tumor mass. Immunohistochemical analysis of 75 pancreatic cancer tissues revealed the presence of strong VEGF immunoreactivity in the cancer cells in 64% of the cancer tissues. The presence of VEGF in these cells was associated with increased blood vessel number, larger tumor size, and enhanced local spread but not with decreased patient survival. These findings indicate that VEGF is commonly overexpressed in human pancreatic cancers and that this factor may contribute to the angiogenic process and tumor growth in this disorder.

UR - http://www.scopus.com/inward/record.url?scp=0030754056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030754056&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 1309

EP - 1316

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -